These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
12. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]. Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963 [TBL] [Abstract][Full Text] [Related]
14. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206 [TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR; Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192 [TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for the treatment of neovascular AMD. Kaiser PK; Do DV Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620 [TBL] [Abstract][Full Text] [Related]
19. Ranibizumab: new drug. Macular degeneration: second-line use due to risks. Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841 [TBL] [Abstract][Full Text] [Related]
20. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]